Autolus Therapeutics (NASDAQ:AUTL) is seeing rising market adoption and revenue as its CAR T therapy demonstrates favorable safety and efficacy in trials and real‑world use, with multiple readouts through 2028; the company also granted stock options and four‑year RSUs in June 2026.
Previous Week Recap
- CAR T Therapy Shows Favorable Safety: Autolus Therapeutics (AUTL): CAR T therapy shows favorable safety and efficacy in trials and real-world use; market adoption and revenue rising, with multiple clinical readouts expected through 2028.
- Autolus Grants Stock Options RSUs: Autolus (AUTL) granted stock options and RSUs on June 24, 2026. Options: $1.66 strike, 10‑year term, 25% after 1 year then monthly vesting; RSUs vest annually over four years.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.